Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Glucose Monitoring, Other Feb 16 | 2021Nemaura Q4 ’20 earnings; MET409 POC Data Published in Journal of HepatologyPurchase Blast
$599
Posted in: Bolus Insulin, Glucagon, Other Feb 12 | 2021Biocon/Viatris Bs-aspart and Xeris RTU Glucagon Receive EC Approval; Poxel Q4 and FY '20 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Glucose Monitoring, Other, SGLT2i Feb 11 | 2021AZ, DXCM, and Teva Q4 '20 Earnings Updates; Supersapiens Partners with Ironman; Praluent Patent Litigation Upheld by US Court of Appeals; REGN Evinacumab Approved in US as Evkeeza; Former Novo Exec Hired as CMO for Hepion PharmaPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Feb 09 | 2021Lannett to Develop Bs-aspart; Seraxis Raises $40M in Series C Funding Round; Bayer Submits Finerenone for DKD in ChinaPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Other Feb 05 | 2021Novo Q4 '20 Post-earnings Event; Sanofi Capital Markets Day 2021; Sanofi and Regeneron Q4 and FY '20 Earnings UpdatesPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Other Feb 04 | 2021ViaCyte Initiates Ph2 Encapsulated Cell Therapy Trial in T1DM; Lannett, Merck, Roche, and BD Q4 and FY '20 Earnings Updates; Merck CEO to RetirePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Other Feb 03 | 2021Novo Broadens Icodec Ph3 program; CSO to Retire; Novo Q4 and FY ’20 Earnings UpdatePurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring Feb 02 | 2021Dexcom Super Bowl DTC; Pfizer Q4 and FY '20 Earnings UpdatePurchase Blast
$599
Posted in: Glucose Monitoring Feb 01 | 2021CGM: SENS/Ascensia Reinitiate EU Eversense XL Commercial Activities; Nemaura Appoints Jay Warner as Head of US Commercial OperationsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA, SGLT2i Jan 29 | 2021Lilly Advances 5 New CV/Met Assets to Ph1; Lilly Q4 and FY '20 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Jan 28 | 2021Lilly and Life for a Child Expand Partnership; ViaCyte Appoints Michael Yang as CEOPurchase Blast
$599
Posted in: Glucose Monitoring, Other Jan 27 | 2021Abbott Q4 ’20 Earnings Update and US DTC; Apple and Samsung Watch CGM?; Dario Acquires Upright TechnologiesPurchase Blast
$599
Posted in: Other, SGLT2i Jan 26 | 2021New Novartis CV Regulatory Comments; Novartis and J&J Q4 '20 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA, Glucagon, SGLT2i Jan 25 | 2021Adocia Reports Positive BC Lispro Data with Tonghua Dongbao Insulin; January 25-29 CHMP AgendaPurchase Blast
$599
Posted in: Basal Insulin Jan 22 | 2021Biocon CY Q4 '20 (FY Q3 '21) Earnings Update; Biocon Biologics CEO ResignsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring Jan 21 | 2021Oramed Randomizes First Patients in Ph3 Oral Insulin Trial; Dario Hires New Employer Sales LeadPurchase Blast
$599
Posted in: Other Jan 20 | 2021Verquvo (Vericiguat) Approved by FDA; Label Analysis, Entresto and CYTK ImplicationsPurchase Blast
$599
Posted in: GLP-1RA, Other Jan 20 | 2021High-Dose Ozempic Filed with FDA; Andy Ajello Joins ViforPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Other Jan 19 | 2021Metacrine NASH Fast Track Designation; Senseonics Receives Positive Coverage Decision for EmblemHealth; Insulet Launches Omnipod DASH in CanadaPurchase Blast